Navigation Links
Latest NIMH Study on Bipolar Disorder

Statement of Ken Duckworth, M.D., Medical Director National Alliance on Mental Illness (NAMI)

ARLINGTON, Va., April 02, 2007 /PRNewswire-USNewswire/ -- Today the Archives of General Psychiatry published a study on the effectiveness of psychosocial treatments for bipolar disorder, "Psychosocial Treatments for Bipolar Disorder." This is a follow up study to one released last Thursday in the New England Journal of Medicine on the effects of antidepressants in the treatment of bipolar disorder. Both studies, called STEP-BD, were funded by the National Institute of Mental Health.

Bipolar disorder is a complex medical illness of the brain that affects 5.7 million Americans.

Ken Duckworth, M.D., medical director of the National Alliance on Mental Illness (NAMI) issued the following statement commenting on the studies:

"Researchers compared the two treatment models, one of which provided 'intensive psychotherapy,' which included weekly sessions in family focused therapy, or interpersonal and social rhythm therapy, or cognitive behavioral therapy; versus 'collaborative care,' which provided three brief psycho educational interventions over a six week period. They found study subjects receiving intensive psychotherapy were 1.58 times more likely be clinically well in a given month and had higher rates of recovery than individuals only receiving collaborative care. This is a call to action for access to these hard-to-find interventions.

The implications of this study are twofold. First, there needs to be more training programs that offer these psychosocial interventions so mental health providers can provide quality care. Second, the study also reminds us of the importance of family in treating people living with bipolar disorder. People who had relationships with family members, in both the control group and the experimental group, had better long-term results with the involvement of their fam ily members.

This study concludes what NAMI members have known for years -- a combination of intensive psychosocial interventions and family involvement are both necessary ingredients for the best outcomes in bipolar disorder. Unfortunately many people who live with serious mental illnesses, like bipolar disorder, don't have access to the most basic care, much less the intensive psychosocial interventions recommended in the study.

The medication arm of the study, released last week in the New England Journal of Medicine, looked at two commonly prescribed antidepressants along with mood stabilizers for the symptoms of depression in individuals who have a diagnosis of bipolar disorder. The study found that the two antidepressants they studied did not work to relieve the depressive symptoms of the illness any better than placebo did for people with bipolar illness. The depressive phase of bipolar illness is notoriously difficult to treat, and more will have to be uncovered as to which pharmacologic strategies best complement the psychosocial treatments for this aspect of bipolar disorder. Most people with bipolar illness spend much more time in the depressive phase, so the need for more effective treatments is profound.

What we learn from these studies is that the treatment of bipolar disorder is an important public health concern, and one that demands individualized attention. We need to provide greater access to intensive psychotherapy to truly offer the hope of recovery to millions of Americans living with bipolar disorder."

Archives of General Psychiatry: http://archpsyc.ama-assn.org/


    New England Journal of Medicine article:

http://content.nejm.org/cgi/content/full/NEJMoa064135


CONTACT: Alexis O'Brien of NAMI, +1-703-312-7893

Web site: http://www.nami.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... LOS ANGELES , Feb. 10, 2016  Oxis ... blood cancer drug, OXS-1550, was described as a "clinical ... with the drug went into complete cancer remission. ... the University of Minnesota Masonic Cancer Center. ... the University of Minnesota Masonic Cancer Center. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the field ... D investment round on February 5, 2016. The $15 ... ("Haisco"), a leading Chinese pharmaceutical manufacturer, and was ... Vitalife Partners, Generali Financial Holdings and both the Technion ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... As part ... two webinars in February 2016. Each webinar features a dynamic expert and thoughtful ... benefit their athletes, patients and facilities. Both events are free to attend, but ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
Breaking Medicine News(10 mins):